Drawing for THE NATURE OF HERBAL PHARMACEUTICALS

USPTO serial 75392484

THE NATURE OF HERBAL PHARMACEUTICALS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
WILLIAMS KELLY L.
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with THE NATURE OF HERBAL PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

BERNARD R GANS

BERNARD R GANS JEFFER MANGELS BUTLER & MARMARO LLP2121 AVE OF THE STARS 10TH FLLOS ANGELES, CA 90067-5010UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICALS AND PHARMACEUTICAL PREPARATIONS BASED ON NATURAL MEDICINES THAT ARE USED TO TREAT PREMENSTRUAL STRESS, REGULATE THE MENSTRUAL CYCLE, PROMOTE THE MENSTRUAL FLOW, REDUCE MENSTRUAL PAIN AND DISCOMFORT, INCREASE BREAST MILK PRODUCTION AND ALTER HORMONE AMOUNTS THAT CAUSE BREAST MILK PRODUCTION, CAUSE SIGNIFICANT DIARRHEA, IMPROVE WOUND HEALING AND SUPERFICIAL WOUND HEALING, REDUCE SKIN INFLAMMATION, REDUCE ITCHING, PROTECT AND REDUCE STRESS TO THE LIVER AND PROTECT AGAINST DAMAGE CAUSED TO THE LIVER, NAMELY, SCARRING, CIRRHOSIS, INFLAMMATION AND HEPATITIS, TREAT ARTHRITIS, DEGENERATIVE ARTHRITIS AND RHEUMATISM, REDUCE DIARRHEA AND INFLAMMATION, REDUCE MUSCLE AND JOINT PAIN, TREAT SORE THROAT PAIN, CAUSE SLEEPINESS AND TREAT INSOMNIA, TREAT BRONCHITIS, BRONCHIAL ASTHMA AND ASTHMA, REDUCE CRAMPING PAIN, REDUCE DIGESTIVE TRACT DISTRESS, TREAT HEMORRHOIDS, TREAT SWELLING DUE TO INSUFFICIENT BLOOD FLOW IN VEINS, VARICOSE VEINS AND CALF CRAMPING PAIN, TREAT INADEQUATE BLOOD FLOW IN THE BRAIN, INCREASE RESISTANCE TO BACTERIAL AND VIRUS INFECTIONS, ASSIST THE TREATMENT OF RECURRING RESPIRATORY AND URINARY TRACT INFECTIONS; REDUCE OUTBREAKS OF SKIN ECZEMA, REDUCE MIGRAINE HEADACHE PAIN, REDUCE FATTY SUBSTANCES IN THE BLOOD, NAMELY, TRIGLYCERIDES AND CHOLESTEROL, REDUCE THE STICKINESS OF PLATELETS AND CLOTTING, INCREASE THE BREAKDOWN OF BLOOD CLOTS, REDUCE NAUSEA BY ACTING ON THE DIGESTIVE TRACT, TREAT RINGING IN THE EARS, TREAT ABNORMAL CHANGES IN THE RETINA, INCREASE SEXUAL DESIRE, TREAT CANCER, INCREASE LIFE EXPECTANCY, IMPROVE HEART FUNCTION, TREAT HEART CONDITIONS ASSOCIATED WITH THE ELDERLY, MILD HEART PAIN BROUGHT ON BY EXERTION, ANGINA, AND MILD IRREGULAR HEART BEAT, LOWER BLOOD PRESSURE, REDUCE INTESTINAL TRACT DISTRESS, TREAT ULCERS, REDUCE PAIN AND INFLAMMATION; ACT AS A FREE RADICAL SCAVENGER AND ANTIOXIDANT, IMPROVE URINATION AND HELP THE BODY REMOVE EXCESS FLUID THROUGH URINATION, TREAT NON-CANCEROUS ENLARGEMENTS OF THE MALE PROSTATE GLAND AND SYMPTOMS CAUSED BY NON-CANCEROUS ENLARGEMENTS AND OTHER DISORDERS OF THE MALE PROSTATE GLAND, HELP RID THE BODY OF WORMS, TREAT DIABETES, STIMULATE AND MODIFY THE BODY'S IMMUNE SYSTEM AND TREAT IMMUNODEFICIENCIES, ASSIST IN THE TREATMENT OF AIDS, REDUCE STRESS CAUSED BY ENVIRONMENTAL FACTORS AND PROMOTE CALM, TREAT MILD TO MODERATE MOOD DEPRESSION, HELP PROTECT A DEVELOPMENT FETUS AGAINST DAMAGE FROM EXPOSURE TO DRUGS, CHEMICALS AND OTHER HARMFUL SUBSTANCES, STIMULATE HAIR GROWTH, AND ARE GENERAL TONICS, NAMELY, SUBSTANCES PRODUCING HEALTHY MUSCULAR CONDITION AND REACTION OF ORGANSACTIVE—
040PHARMACEUTICAL MANUFACTURING TO THE ORDER AND SPECIFICATIONS OF OTHERSACTIVE—
042PHARMACEUTICAL RESEARCH, NAMELY, MEDICAL RESEARCH IN THE NATURE OF IDENTIFYING AND QUANTIFYING THE ACTIVE AND EFFECTIVE COMPONENTS OF NATURAL MEDICINES SO THAT PHARMACEUTICAL VERSIONS CAN BE MADE AND TESTEDACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 30, 2001ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 30, 2000NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 7, 2000PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 4, 2000NPUBNOTICE OF PUBLICATION—
Nov 12, 1999CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 26, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 26, 1999CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 19, 1998CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 1998CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 16, 1998DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance